[Irinotecan and liver dysfunctions].
During last years, irinotecan has become registered as a major cytotoxic drug in several tumor types. Since the metabolism of this drug is predominantly made in the liver, administration to patients with liver dysfunctions remains a major problem. Hyperbilirubinemia has been shown to require dose reduction. In addition, gene polymorphism of UGT1A1 was shown to be associated with a higher risk of toxicity. However, studies are still required to optimise the use of irinotecan in patients with liver dysfunctions.
Sablin
Marie-Paule
MP
Service Inter Hospitalier de Cancérologie Bichat-Beaujon, Hôpital Beaujon, 100 boulevard du Général Leclerc, 92118 Clichy Cedex, France.
Le Tourneau
Christophe
C
Faivre
Sandrine
S
Raymond
Eric
E
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000493:pharmacokinetics; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D000077146:Irinotecan; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008111:Liver Function Tests; D009369:Neoplasms / Q000188:drug therapy*; D011110:Polymorphism, Genetic
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D014453:Glucuronosyltransferase; D002166:Camptothecin